those who experienced breakthrough infection in the aforementioned GVHD prophylaxis study (2) . A study evaluating posaconazole as salvage therapy for invasive aspergillosis correlated therapeutic response to serum drug concentrations by quartiles and found those with a mean serum drug level of 0.134 g/ml had only a 24% response rate (9) . Additionally, the FDA briefing document recommends a goal posaconazole average serum drug concentration of Ͼ0.700 g/ml (3).
We retrospectively reviewed 202 consecutive serum posaconazole concentrations obtained between 26 December 2007 and 30 December 2008 by The Fungus Testing Laboratory, San Antonio, TX, a reference laboratory specializing in fungal identification, susceptibility testing, and antifungal drug concentrations. Drug levels were obtained with a validated highperformance liquid chromatography assay (range, 0.125 to 5.0 g/ml [equipment manufactured by Beckman Coulter, Fullerton, CA]). Levels less than 0.125 g/ml were reported as undetectable, and levels greater than 5.0 g/ml were diluted 1:2, reextracted, and reanalyzed.
Our review confirmed the infrequent obtainment of levels suggestive of efficacy as described above. In our series, 158/202 (78.2%) posaconazole levels were Ͻ0.92 g/ml and 135/202 (66.8%) were Ͻ0.611 g/ml, a value that may represent patients at increased risk of breakthrough infection while receiving posaconazole prophylaxis. Although the exact value known to be therapeutic in the treatment of invasive mycoses has not been determined, it is noteworthy that 33/202 (16.3%) in our series were undetectable (Ͻ0.125), 35/202 (17.3%) were Ͻ0.134 g/ml (the value associated with only a 24% response rate in posaconazole use as salvage therapy for invasive aspergillosis), and 142/202 (70.3%) were Ͻ0.700 g/ml (the value cited by the FDA to place patients at increased risk) (Fig. 1) .
When drug concentrations thought to be subtherapeutic are observed, attempts at maximizing drug availability/absorption should be undertaken. Strategies proven to maximize posaconazole exposure include administration with or after a high-fat meal, with any meal or nutritional supplement, with an acidic beverage, or in divided doses and with the avoidance of acid suppression drugs (6) . However, it is common for low serum posaconzole levels to be found despite these maneuvers, and these differences observed between serum drug levels within clinical trials and "real-world" use may have an important clinical impact on the frequency of TDM and choice of antifungal agent. We thus recommend repeat testing of serum posaconazole levels after the above attempts to maximize absorption. Although previous reports have questioned the need for TDM with posaconazole pending outcome studies based on levels, our data suggest that testing should be performed to ensure that measurable drug is present and therefore has the potential for efficacy.
